Effect of the glucocorticoid receptor antagonist Org 34850 on basal and stress-induced corticosterone secretion

Journal of Neuroendocrinology

Volumn 19, Issue 11, 2007, Pages 891-900

  Spiga, Francesca ^a   Harrison, L R ^a   Wood, S A ^a   Atkinson, H C ^a   MacSweeney, C P ^b   Thomson, F ^b   Craighead, M ^b   Grassie, M ^b   Lightman, S L ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Corticosterone; Depression; Glucocorticoid receptor antagonist; Glucocorticoids; Stress

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; GLUCOCORTICOID RECEPTOR ANTAGONIST; MESSENGER RNA; METHYLPREDNISOLONE SODIUM SUCCINATE; ORG 34850; UNCLASSIFIED DRUG;

ADENOHYPOPHYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CIRCADIAN RHYTHM; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEEDBACK SYSTEM; GENE EXPRESSION; HIPPOCAMPUS; HORMONE RELEASE; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MOOD DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; STRESS; THALAMUS MIDLINE NUCLEUS;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; CIRCADIAN RHYTHM; CORTICOSTERONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IN SITU HYBRIDIZATION; MALE; PITUITARY-ADRENAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCOCORTICOID; STEROIDS; STRESS, PSYCHOLOGICAL; SULFONES;

EID: 35048824928     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2007.01605.x     Document Type: Article

References (52)

1. Jasper MS, Engeland WC. Synchronous ultradian rhythms in adrenocortical secretion detected by microdialysis in awake rats. Am J Physiol 1991; 261: R1257-R1268.
2. Windle RJ, Wood SA, Lightman SL, Ingram CD. The pulsatile characteristics of hypothalamo-pituitary-adrenal activity in female Lewis and Fischer 344 rats and its relationship to differential stress responses. Endocrinology 1998; 139: 4044-4052.
3. Dallman MF, Akana SF, Cascio CS, Darlington DN, Jacobson L, Levin N. Regulation of ACTH secretion: Variations on a theme of B. Recent Prog Horm Res 1987; 43: 113-173.
4. Reul JM, De Kloet ER. Two receptor systems for corticosterone in rat brain: Microdistribution and differential occupation. Endocrinology 1985; 117: 2505-2511.
5. Spencer RL, Miller AH, Stein M, Mcewen BS. Corticosterone regulation of type I and type II adrenal steroid receptors in brain, pituitary, and immune tissue. Brain Res 1991; 549: 236-246.
6. Spencer RL, Young EA, Choo PH, Mcewen BS. Adrenal steroid type I and type II receptor binding: Estimates of in vivo receptor number, occupancy, and activation with varying level of steroid. Brain Res 1990; 514: 37-48.
7. Kitchener PBF, Borrelli E, Piazza PV. Differences between brain structures in nuclear translocation and DNA binding of the glucocorticoid receptor during stress and the circadian cycle. Eur J Neurosci 2004; 19: 1837-1846.
8. Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: Implications for therapy. J Affect Disord 2001; 62: 77-91.
9. Michael RP, Gibbons JL. Interrelationships between the endocrine system and neuropsychiatry. Int Rev Neurobiol 1963; 5: 243-302.
10. Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: New findings and new directions. Mol Psychiatry 1996; 1: 336-342.
11. Halbreich U, Asnis GM, Shindledecker R, Zumoff B, Nathan RS. Cortisol secretion in endogenous depression. I. Basal plasma levels. Arch Gen Psychiatry 1985; 42: 904-908.
12. Linkowski P, Mendlewicz J, Leclercq R, Brasseur M, Hubain P, Golstein J, Van Copinschi G, CE. The 24-hour profile of adrenocorticotropin and cortisol in major depressive illness. J Clin Endocrinol Metab 1985; 61: 429-438.
13. Deuschle M, Schweiger U, Weber B, Gotthardt U, Korner A, Schmider J, Standhardt H, Lammers CH, Heuser I. Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab 1997; 82: 234-238.
14. Carroll BJ, Curtis GC, Davies BM, Mendels J, Sugerman AA. Urinary free cortisol excretion in depression. Psychol Med 1976; 6: 43-50.
15. Amsterdam JD, Winokur A, Bryant S, Larkin J, Rickels K. The dexamethasone suppression test as a predictor of antidepressant response. Psychopharmacology (Berl) 1983; 80: 43-45.
16. Nemeroff CB, Krishnan KR, Reed D, Leder R, Beam C, Dunnick NR. Adrenal gland enlargement in major depression. A computed tomographic study. Arch Gen Psychiatry 1992; 49: 384-387.
17. Pariante CM. Glucocorticoid receptor function in vitro in patients with major depression. Stress 2004; 7: 209-219.
18. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501.
19. Webster MJ, Knable MB, O'Grady J, Orthmann J, Weickert CS. Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Mol Psychiatry 2002; 7: 924.
20. Peiffer A, Veilleux S, Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology 1991; 16: 505-515.
21. Pepin MC, Govindan MV, Barden N. Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol 1992; 41: 1016-1022.
22. Przegalinski E, Budziszewska B, Siwanowicz J, Jaworska L. The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology 1993; 32: 1397-1400.
23. Przegalinski E, Budziszewska B. The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats. Neurosci Lett 1993; 161: 215-218.
24. Pepin MC, Pothier F, Barden N. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression. Mol Pharmacol 1992; 42: 991-995.
25. Debattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry 2006; 60: 1343-1349.
26. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006; 31: 628-636.
27. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004; 29: 1538-1545.
28. Gagne D, Pons M, Philibert D. RU 38486: A potent antiglucocorticoid in vitro and in vivo. J Steroid Biochem 1985; 23: 247-251.
29. Gruol DJ, Altschmied J. Synergistic induction of apoptosis with glucocorticoids and 3′,5′-cyclic adenosine monophosphate reveals agonist activity by RU 486. Mol Endocrinol 1993; 7: 104-113.
30. Havel PJ, Busch BL, Curry DL, Johnson PR, Dallman MF, Stern JS. Predominately glucocorticoid agonist actions of RU-486 in young specific-pathogen-free Zucker Rats. Am J Physiol 1996; 271: R710-R717.
31. Peeters BW, Tonnaer JA, Groen MB, van Broekkamp CL, d V, Schoonen WG, Smets RJ, Vanderheyden PM, Gebhard R, Ruigt GS. Glucocorticoid receptor antagonists: New tools to investigate disorders characterized by cortisol hypersecretion. Stress 2004; 7: 233-241.
32. Clark RG, Chambers G, Lewin J, Robinson IC. Automated repetitive microsampling of blood: Growth hormone profiles in conscious male rats. J Endocrinol 1986; 111: 27-35.
33. Windle RJ, Wood S, Shanks N, Perks P, Conde GL, da Costa AP, Ingram CD, Lightman SL. Endocrine and behavioural responses to noise stress: comparison of virgin and lactating female rats during non-disrupted maternal activity J Neuroendocrinol 1997; 9: 407-414.
34. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Orlando, FL: Academic Press, 1986.
35. Seckl JR, Dickson KL, Yates C, Fink G. Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human postmortem hippocampus. Brain Res 1991; 561: 332-337.
36. Merriam GR, Wachter KW. Algorithms for the study of episodic hormone secretion. Am J Physiol 1982; 243: E310-E318.
37. Spencer RL, Kim PJ, Kalman BA, Cole MA. Evidence for mineralocorticoid receptor facilitation of glucocorticoid receptor-dependent regulation of hypothalamic-pituitary-adrenal axis activity. Endocrinology 1998; 139: 2718-2726.
38. van Haarst AD, Oitzel MS, De Kloet ER. Facilitation of feedback inhibition through blockade of glucocorticoid receptors in the hippocampus. Neurochem Res 1997; 22: 1323-1328.
39. Bachmann CG, Linthorst AC, Holsboer F, Reul JM. Effect of chronic administration of selective glucocorticoid receptor antagonists on the rat hypothalamic-pituitary-adrenocortical axis. Neuropsychopharmacology 2003; 28: 1056-1067.
40. Kim PJ, Cole MA, Kalman BA, Spencer RL. Evaluation of RU28318 and RU40555 as selective mineralocorticoid receptor and glucocorticoid receptor antagonists, respectively: Receptor measures and functional studies. J Steroid Biochem Mol Biol 1998; 67: 213-222.
41. Bertagna X, Bertagna C, Luton JP, Husson JM, Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 1984; 59: 25-28.
42. Bertagna X, Escourolle H, Pinquier JL, Coste J, Raux-Demay MC, Perles P, Silvestre L, Luton JP, Strauch G. Administration of RU 486 for 8 days in normal volunteers: Antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J Clin Endocrinol Metab 1994; 78: 375-380.
43. Lamberts SW, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 1991; 73: 187-191.
44. Jewell CM, Webster JC, Burnstein KL, Sar M, Bodwell JE, Cidlowski JA. Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors. J Steroid Biochem Mol Biol 1995; 55: 135-146.
45. Pariante CM, Pearce BD, Pisell TL, Su C, Miller AH. The steroid receptor antagonists RU40555 and RU486 activate glucocorticoid receptor translocation and are not excreted by the steroid hormones transporter in L929 cells. J Endocrinol 2001; 169: 309-320.
46. Rupprecht R, van Reul JMSB, Spengler D, Soder M, Berning B, Holsboer F, Damm K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol 1993; 247: 145-154.
47. Carnes M, Lent S, Feyzi J, Hazel D. Plasma adrenocorticotropic hormone in the rat demonstrates three different rhythms within 24 h. Neuroendocrinology 1989; 50: 17-25.
48. Engeland WC, Arnhold MM. Neural circuitry in the regulation of adrenal corticosterone rhythmicity. Endocrine 2005; 28: 325-332.
49. Ulrich-Lai YM, Arnhold MM, Engeland WC. Adrenal splanchnic innervation contributes to the diurnal rhythm of plasma corticosterone in rats by modulating adrenal sensitivity to ACTH. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1128-R1135.
50. Bradbury MJ, Akana SF, Cascio CS, Levin N, Jacobson L, Dallman MF. Regulation of basal ACTH secretion by corticosterone is mediated by both type I (MR) and type II (GR) receptors in rat brain. J Steroid Biochem Mol Biol 1991; 40: 133-142.
51. Ratka A, Sutanto W, Bloemers M, de Kloet ER. On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology 1989; 50: 117-123.
52. Weidenfeld J, Feldman S. Glucocorticoid feedback regulation of adrenocortical responses to neural stimuli: Role of CRF-41 and corticosteroid type I and type II receptors Neuroendocrinology 1993; 58: 49-56.